- Home
- SYBX vs IBIO Comparison
SYBX vs IBIO Comparison
Compare SYBX & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- IBIO
- Stock Information
- Founded
- SYBX N/A
- IBIO 2008
- Country
- SYBX United States
- IBIO United States
- Employees
- SYBX N/A
- IBIO N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- IBIO Health Care
- Exchange
- SYBX Nasdaq
- IBIO Nasdaq
- Market Cap
- SYBX 20.0M
- IBIO 16.4M
- IPO Year
- SYBX N/A
- IBIO N/A
- Fundamental
- Price
- SYBX $1.77
- IBIO $1.20
- Analyst Decision
- SYBX
- IBIO Strong Buy
- Analyst Count
- SYBX 0
- IBIO 4
- Target Price
- SYBX N/A
- IBIO $4.50
- AVG Volume (30 Days)
- SYBX 35.2K
- IBIO 6.7M
- Earning Date
- SYBX 11-11-2025
- IBIO 11-11-2025
- Dividend Yield
- SYBX N/A
- IBIO N/A
- EPS Growth
- SYBX N/A
- IBIO N/A
- EPS
- SYBX N/A
- IBIO N/A
- Revenue
- SYBX N/A
- IBIO $400,000.00
- Revenue This Year
- SYBX N/A
- IBIO N/A
- Revenue Next Year
- SYBX N/A
- IBIO N/A
- P/E Ratio
- SYBX N/A
- IBIO N/A
- Revenue Growth
- SYBX N/A
- IBIO 77.78
- 52 Week Low
- SYBX $0.90
- IBIO $0.56
- 52 Week High
- SYBX $1.96
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- SYBX 56.70
- IBIO 65.01
- Support Level
- SYBX $1.64
- IBIO $1.02
- Resistance Level
- SYBX $1.87
- IBIO $1.72
- Average True Range (ATR)
- SYBX 0.09
- IBIO 0.15
- MACD
- SYBX -0.00
- IBIO 0.05
- Stochastic Oscillator
- SYBX 64.91
- IBIO 42.46
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.